1
|
Schnittler M, Inoue M, Shchepin ON, Fuchs J, Chang H, Lamkowski P, Knapp R, Horn K, Bennert HW, Bog M. Hybridization and reticulate evolution in Diphasiastrum (flat-branched clubmosses, Lycopodiaceae) - New data from the island of Taiwan and Vietnam. Mol Phylogenet Evol 2024; 196:108067. [PMID: 38561082 DOI: 10.1016/j.ympev.2024.108067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Revised: 03/20/2024] [Accepted: 03/21/2024] [Indexed: 04/04/2024]
Abstract
In the species groups related to Diphasiastrum multispicatum and D. veitchii, hybridization was investigated in samples from northern and southern Vietnam and the island of Taiwan, including available herbarium specimens from southeast Asia. The accessions were analyzed using flow cytometry (living material only), Sanger sequencing and multiplexed inter-simple sequence repeat genotyping by sequencing. We detected two cases of ancient hybridization involving different combinations of parental species; both led via subsequent duplication to tetraploid taxa. A cross D. multispicatum × D. veitchii from Malaysia represents D. wightianum, a tetraploid taxon according to reported DNA content measurements of dried material (genome formulas MM, VV and MMVV, respectively). The second case involves D. veitchii and an unknown diploid parent (genome formula XX). Three hybridogenous taxa (genome formulas VVX, VVXX, VVVX) were discernable by a combination of flow cytometry and molecular data. Taxon I (VVX, three clones found on Taiwan island) is apparently triploid. Taxon II represents another genetically diverse and sexual tetraploid species (VVXX) and can be assigned to D. yueshanense, described from Taiwan island but occurring as well in mainland China and Vietnam. Taxon III is as well most likely tetraploid (VVVX) and represented by at least one, more likely two, clones from Taiwan island. Taxa I and III are presumably asexual and new to science. Two independently inherited nuclear markers recombine only within, not between these hybrids, pointing towards reproductive isolation. We present an evolutionary scheme which explains the origin of the hybrids and the evolution of new and fully sexual species by hybridization and subsequent allopolyploidization in flat-branched clubmosses.
Collapse
Affiliation(s)
- M Schnittler
- Institute of Botany and Landscape Ecology, Ernst Moritz Arndt University of Greifswald, Soldmannstraße 15, D-17487 Greifswald, Germany
| | - M Inoue
- Institute of Botany and Landscape Ecology, Ernst Moritz Arndt University of Greifswald, Soldmannstraße 15, D-17487 Greifswald, Germany
| | - O N Shchepin
- Institute of Botany and Landscape Ecology, Ernst Moritz Arndt University of Greifswald, Soldmannstraße 15, D-17487 Greifswald, Germany
| | - J Fuchs
- Leibniz-Institute of Plant Genetics and Crop Plant Research (IPK), Corrensstraße 3, Stadt Seeland, D-06466 OT Gatersleben, Germany
| | - H Chang
- Division of Botany, Endemic Species Research Institute, 1, Ming Seng E. Road, Jiji, Nantou 552, Taiwan, ROC
| | - P Lamkowski
- Nature Conservation and Land Use Planning, University of Applied Sciences Neubrandenburg, Brodaer Straße 2, D-17033 Neubrandenburg, Germany
| | - R Knapp
- Steigestraße 78, D-69412 Eberbach, Germany
| | - K Horn
- Büro für angewandte Geobotanik und Landschaftsökologie (BaGL), Frankenstraße 2, D-91077 Dormitz, Germany
| | - H W Bennert
- Evolution and Biodiversity of Plants, Ruhr-Universität Bochum, D-44780 Bochum, Germany
| | - M Bog
- Institute of Botany and Landscape Ecology, Ernst Moritz Arndt University of Greifswald, Soldmannstraße 15, D-17487 Greifswald, Germany.
| |
Collapse
|
2
|
Hagihara M, Hayashi H, Nakashima S, Imai Y, Nakano H, Uchida T, Inoue M, Sakai-Tagawa Y, Ito M, Yamayoshi S, Iwatsuki-Horimoto K, Suzuki Y, Kawaoka Y. Clinical Efficacy of Imdevimab/Casirivimab for Persistent Omicron SARS-CoV-2 Infection in Patients with Hematological Malignancies. Intern Med 2024:2900-23. [PMID: 38171874 DOI: 10.2169/internalmedicine.2900-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2024] Open
Abstract
Objective Prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been reported in immunocompromised patients, as they poorly develop antibodies against SARS-CoV-2. We conducted a clinical trial to determine the efficacy of Imdevimab/Casirivimab (Imde/Casiri), an anti-viral monoclonal antibody (mAb), for prolonged infection at our institution. Methods Nine patients with hematological malignancies (six with malignant lymphoma and three with multiple myeloma) in our institution presented with coronavirus disease 2019 caused by SARS-CoV-2 omicron variants (one, five, and one with BA.2, BA.5, and BF.7, respectively; two undetermined). Although not all nine patients developed severe disease, viral mRNA was detected in all patients after treatment with remdesivir or molnupiravir. Imde/casiri was infused 11-49 days after the disease onset. Results Within seven days of infusion, viral RNA was undetectable in five of the nine cases. Because all seven viruses isolated from patients whose viral RNA became undetectable showed low or no sensitivity to this monoclonal antibody cocktail, the disappearance of viral RNA in these cases may not be attributable to the antibody cocktail. Conclusion It may be worth considering the use of monoclonal antibodies that show some activity against these virus variants to treat persistent SARS-CoV-2 infection in immunocompromised patients.
Collapse
Affiliation(s)
| | | | | | - Yui Imai
- Department of Hematology, Eiju General Hospital, Japan
| | | | | | | | - Yuko Sakai-Tagawa
- Division of Virology, Institute of Medical Science, University of Tokyo, Japan
| | - Mutsumi Ito
- Division of Virology, Institute of Medical Science, University of Tokyo, Japan
| | - Seiya Yamayoshi
- Division of Virology, Institute of Medical Science, University of Tokyo, Japan
- The Research Center for Global Viral Disease, Research Institute, National Center for Global Health and Medicine, Japan
| | | | - Yutaka Suzuki
- Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Japan
| | - Yoshihiro Kawaoka
- Division of Virology, Institute of Medical Science, University of Tokyo, Japan
- The Research Center for Global Viral Disease, Research Institute, National Center for Global Health and Medicine, Japan
- Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), University of Tokyo, Japan
- Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, USA
| |
Collapse
|
3
|
Nakashima S, Ohara S, Imai Y, Nakano H, Uchida T, Inoue M, Hagihara M. [Diffuse large B-cell lymphoma concurrent with Kaposi's sarcoma in the same lymph node in a human immunodeficiency virus-negative patient]. Rinsho Ketsueki 2024; 65:74-77. [PMID: 38448001 DOI: 10.11406/rinketsu.65.74] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/08/2024]
Abstract
An 80-year-old Japanese man presented with systemic lymphadenopathy, including the para-aortic area and left inguinal nodes, which was diagnosed as diffuse large B-cell lymphoma (DLBCL) and human herpesvirus (HHV) 8-positive/HIV-negative Kaposi's sarcoma (KS). Immunohistochemical examination revealed that the lymphoma cells were negative for HHV-8. The patient received combined chemotherapy with rituximab, pirarubicin, cyclophosphamide, vincristine, and prednisolone for six cycles and achieved complete remission. In the literature, five cases of simultaneous appearance of malignant lymphoma and KS in the same lymph node have been reported, but DLBCL as a histological subtype has not yet been reported.
Collapse
Affiliation(s)
| | - Shin Ohara
- Department of Hematology, Eiju General Hospital
| | - Yui Imai
- Department of Hematology, Eiju General Hospital
| | | | | | | | | |
Collapse
|
4
|
Maezawa M, Inoue M, Satake R, Wakabayashi W, Oura K, Goto F, Miyasaka K, Hirofuji S, Iwata M, Suzuki T, Tanaka H, Nishida S, Shimizu S, Suzuki A, Iguchi K, Nakamura M. Effect of acid suppressant medications on the laxative action of magnesium preparations in patients with opioid-induced constipation: A pharmacovigilance analysis of the FDA Adverse Event Reporting System. Pharmazie 2023; 78:245-250. [PMID: 38178284 DOI: 10.1691/ph.2023.3624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/06/2024]
Abstract
Objective: Magnesium oxide is widely used for treating opioid-induced constipation, a serious analgesic-associated problem. Opioid analgesic users are often prescribed non-steroidal anti-inflammatory drugs, which are sometimes combined with acid suppressants to prevent gastrointestinal adverse events. Magnesium preparations combined with acid suppressants may diminish magnesium preparations' laxative effect. This study was aimed at evaluating the effect of magnesium preparations combined with acid suppressants on the incidence of opioid-induced constipation by using the Food and Drug Administration Adverse Event Reporting System. Methods: Adverse events were defined per the Medical Dictionary for Regulatory Activities; the term 'constipation (preferred term code: 10010774)' was used for analysis. After adjusting for patient background factors using propensity score matching, acid suppressants' effect on constipation incidence was evaluated in opioid users prescribed magnesium preparations alone as laxatives by using a test for independence. Key Findings: The Food and Drug Administration Adverse Event Reporting System contains 14,475,614 reports for January 2004 to December 2021. Significantly increased constipation incidence was related to magnesium preparations combined with acid suppressants, especially proton pump inhibitors (P < 0.0001, McNemar's test). Conclusion: Magnesium preparations combined with acid suppressants may diminish magnesium preparations' laxative effect; healthcare professionals should pay attention to this issue.
Collapse
Affiliation(s)
- M Maezawa
- Laboratory of Drug Informatics, Gifu Pharmaceutical Universit
| | - M Inoue
- Laboratory of Drug Informatics, Gifu Pharmaceutical University
| | - R Satake
- Laboratory of Drug Informatics, Gifu Pharmaceutical University
| | - W Wakabayashi
- Laboratory of Drug Informatics , Gifu Pharmaceutical University
| | - K Oura
- Laboratory of Drug Informatics, Gifu Pharmaceutical University
| | - F Goto
- Laboratory of Drug Informatics, Gics, Gifu Pharmaceutical University
| | - K Miyasaka
- Laboratory of Drug Informatics, Gics, Gifu Pharmaceutical University
| | - S Hirofuji
- Laboratory of Drug Informatics, Gifu Pharmaceutical University
| | - M Iwata
- Laboratory of Drug Informatics, Gifu Pharmaceutical University; Kifune Pharmacy
| | - T Suzuki
- Laboratory of Drug Informatics, Gifu Pharmaceutical University; Gifu Prefectural Government
| | - H Tanaka
- Laboratory of Drug Informatics, Gifu Pharmaceutical University; Chubu Yakuhin Co. Ltd
| | - S Nishida
- Department of Pharmacy, Gifu University Hospital
| | - S Shimizu
- Department of Pharmacy, Gifu University Hospital
| | - A Suzuki
- Department of Pharmacy, Gifu University Hospital
| | - K Iguchi
- Laboratory of Community Pharmacy, Gifu Pharmaceutical University, Gifu, Japan
| | - M Nakamura
- Laboratory of Drug Informatics, Gifu Pharmaceutical University; Corresponding author: Mitsuhiro Nakamura, Laboratory of Drug Informatics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196, Japan mnakamura@gifu-pu. ac. jp
| |
Collapse
|
5
|
Sugi T, Mita M, Kushi R, Hanai H, Uchida T, Inoue M, Hagihara M. Prevention of pneumocystis pneumonia in patients with hematological diseases: Efficacy of low-dose atovaquone. Int J Clin Pharmacol Ther 2023; 61:515-519. [PMID: 37622674 DOI: 10.5414/cp204368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/10/2023] [Indexed: 08/26/2023] Open
Abstract
OBJECTIVE At our institution, patients with hematological disease who require Pneumocystis jirovecii pneumonia (PJP) prophylaxis were administered atovaquone at a low dose (750 mg/day). However, there have been few reports on the efficacy of low-dose atovaquone administration, and the purpose of this study is, therefore, to investigate its effectiveness. MATERIALS AND METHODS We investigated the expression of PJP in patients with hematological disease who received atovaquone administration. Atovaquone was administered at a low dose of 750 mg once daily, and the follow-up time was the period of PJP prophylaxis that included atovaquone administration. RESULTS 85 patients were included in the study. The median age of the study population was 72 years (range: 33 - 97). The duration of atovaquone treatment and follow-up time were 150 days (22 - 1,018) and 258 days (22 - 1,457), respectively. In hematologic diseases, multiple myeloma was high in 31 patients and malignant lymphoma in 28 patients. No patients exhibited PJP during the observation period. CONCLUSION In hematological disease patients with relatively low risk of PJP, low-dose atovaquone may prevent the onset of PJP.
Collapse
|
6
|
Doi Y, Nagata Y, Matsumo Y, Numata K, Sasaki R, Yamada T, Igaki H, Imagumbai T, Katoh N, Yoshitake T, Shimizuguchi T, Fujioka D, Inoue M, Koide Y, Kimura T, Ito Y. Multicenter Retrospective Study of Stereotactic Body Radiotherapy for Patients with Previously Untreated Initial Small Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2023; 117:e293. [PMID: 37785079 DOI: 10.1016/j.ijrobp.2023.06.1290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The effectiveness of stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) has been shown in many studies and its therapeutic effect is similar to radiofrequency ablation (RFA). However, many of these studies were done in combination with transcatheter chemoembolization (TACE), for recurrent HCC, or on a small scale. To better understand the specific outcomes of SBRT for HCC, we conducted a multicenter retrospective analysis of SBRT for previously untreated initial HCC at Japanese Society of Clinical Oncology (JCOG) member hospitals. MATERIALS/METHODS Patientswho underwent SBRT for HCC at JCOG member hospitals between July 2013 and December 2017 and met the following eligibility criteria were included: (1) initial HCC; (2) ≤ 3 nodules, ≤ 5 cm in diameter; (3) a Child-Pugh (CP) score of A or B; and (4) unsuitability for or refusal of standard treatment, such as surgery, transplantation, RFA and TACE. We evaluated the overall survival (OS), recurrence-free survival (RFS) which was defined as the first instance of intra-hepatic recurrence after SBRT, disease-specific survival (DSS) using Kaplan-Meier analysis. Using Grey's test, patients who died of other diseases were analyzed as competing risks to estimate the cumulative incidence of local recurrence (CLR). Adverse events directly related to SBRT also analyzed using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0). RESULTS Seventy-three patients with 79 lesions from 14 hospitals were analyzed. The median age was 77 years (range; 50-89 years), and the median tumor size was 23 mm (range; 6-50 mm). The median radiation dose was 40 Gy (range; 35-60 Gy) in five fractions (range; 4-8). The median follow-up period was 45 months (range; 0-103 months). There were three cases where follow-up was not possible due to unexpected events unrelated to SBRT, while the remaining 70 patients were successfully followed for at least six months. The 2 and 3year OS, RFS, DSS, and CLR rates were 84.3% (95% CI: 75.8-92.8%) and 69.9% (95% CI: 58.7-81%), 67.5% (95% CI: 56.0-79.0%) and 57.9% (95% CI: 45.2-70.5%), 95.1% (95% CI:89.7-100%)/87.6% (95% CI:78.8-96.3%), and 11.4% (95% CI: 5.3-20.0%) and 20.0% (95% CI: 11.2-30.5%), respectively. Four cases (5.5%) of adverse events of grade 3 or higher were reported: one case of grade 3 laboratory toxicities, one case of grade 3 liver failure, one case of grade 3 portal tumor thrombosis, and one case of grade 4 duodenal ulcer. No grade 5 toxicities were observed. CONCLUSION The results of our study demonstrate that SBRT for HCC is highly effective in achieving local control and is safe to administer. In addition, survival outcomes are favorable. SBRT is a promising treatment modality, especially for small HCCs for that is not suitable for standard treatment.
Collapse
Affiliation(s)
- Y Doi
- Department of Radiation Oncology, Hiroshima High-precision Radiotherapy Cancer Center, Hiroshima, Japan
| | - Y Nagata
- Department of Radiation Oncology, Hiroshima University, Hiroshima, Japan
| | - Y Matsumo
- Department of Radiation oncology, Niigata cancer center hospital, Niigata, Japan
| | - K Numata
- Department of Gastroenterology, Yokohama City University Medical Center, Yokohama, Japan
| | - R Sasaki
- Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - T Yamada
- University of Yamanashi, Chuo, Japan
| | - H Igaki
- Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - T Imagumbai
- Kobe City Medical Center General Hospital, Kobe, Japan
| | - N Katoh
- Department of Radiation Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan
| | - T Yoshitake
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - T Shimizuguchi
- Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
| | - D Fujioka
- Department of Radiation Oncology, Tsukuba University Hospital, Ibaraki, Japan
| | - M Inoue
- Department of Radiation Oncology and Image-applied Therapy, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Y Koide
- Aichi Cancer Center Hospital, Nagoya, Japan
| | - T Kimura
- Department of Radiation Oncology, Kochi University Hospital, Kochi, Japan
| | - Y Ito
- Department of Radiation Oncology, Showa University Hospital, Tokyo, Japan
| |
Collapse
|
7
|
Shimizu Y, Inoue M, Yasuda N, Yamagishi K, Iwasaki M, Tsugane S, Sawada N. Bowel movement frequency, stool consistency, and risk of disabling dementia: a population-based cohort study in Japan. Public Health 2023; 221:31-38. [PMID: 37392635 DOI: 10.1016/j.puhe.2023.05.019] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2022] [Revised: 05/24/2023] [Accepted: 05/27/2023] [Indexed: 07/03/2023]
Abstract
OBJECTIVES This population-based study aimed to evaluate the association between bowel habits from midlife and dementia. STUDY DESIGN This was a cohort study using certification records for national long-term care insurance in Japan. METHODS Participants aged 50 to 79 years who reported bowel habits from eight districts within the Japan Public Health Center-based Prospective Study (JPHC Study) were followed from 2006 to 2016 for incident dementia. Hazard ratio (HR) and 95% confidence interval (CI) were estimated for men and women separately using Cox proportional hazards models accounting for various lifestyle factors and medical histories. RESULTS Among 19,396 men and 22,859 women, 1889 men and 2685 women were diagnosed with dementia. In men, the multivariable-adjusted HRs compared with bowel movement frequency (BMF) of once/day were 1.00 (95% CI: 0.87-1.14) for twice/day or more, 1.38 (1.16-1.65) for 5-6 times/week, 1.46 (1.18-1.80) for 3-4 times/week, and 1.79 (1.34-2.39) for <3 times/week (P for trend <0.001). In women, the corresponding HRs were 1.14 (0.998-1.31), 1.03 (0.91-1.17), 1.16 (1.01-1.33), and 1.29 (1.08-1.55) (P for trend = 0.043). Harder stool was associated with higher risk (P for trend: 0.0030 for men and 0.024 for women), with adjusted HRs compared to normal stool of 1.30 (1.08-1.57) for hard stool and 2.18 (1.23-3.85) for very hard stool in men, and 1.15 (1.002-1.32) and 1.84 (1.29-2.63) in women. CONCLUSIONS Lower BMF and harder stool were each associated with higher risk of dementia.
Collapse
Affiliation(s)
- Y Shimizu
- Division of Epidemiology, National Cancer Center Institute for Cancer Control, Tokyo, Japan
| | - M Inoue
- Division of Cohort Research, National Cancer Center Institute for Cancer Control, Tokyo, Japan; Division of Prevention, National Cancer Center Institute for Cancer Control, Tokyo, Japan
| | - N Yasuda
- Department of Public Health, Kochi University Medical School, Kochi, Japan
| | - K Yamagishi
- Department of Public Health Medicine, Faculty of Medicine, and Health Services Research and Development Center, University of Tsukuba, Tsukuba, Japan
| | - M Iwasaki
- Division of Epidemiology, National Cancer Center Institute for Cancer Control, Tokyo, Japan; Division of Cohort Research, National Cancer Center Institute for Cancer Control, Tokyo, Japan
| | - S Tsugane
- Division of Cohort Research, National Cancer Center Institute for Cancer Control, Tokyo, Japan; National Institute of Health and Nutrition, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
| | - N Sawada
- Division of Cohort Research, National Cancer Center Institute for Cancer Control, Tokyo, Japan.
| |
Collapse
|
8
|
Hayashi K, Tanaka Y, Tsuda T, Nomura A, Fujino N, Furusho H, Sakai N, Iwata Y, Usui S, Sakata K, Kato T, Tada H, Kusayama T, Usuda K, Kawashiri MA, Passman RS, Wada T, Yamagishi M, Takamura M, Fujino N, Nohara A, Kawashiri MA, Hayashi K, Sakata K, Yoshimuta T, Konno T, Funada A, Tada H, Nakanishi C, Hodatsu A, Mori M, Tsuda T, Teramoto R, Nagata Y, Nomura A, Shimojima M, Yoshida S, Yoshida T, Hachiya S, Tamura Y, Kashihara Y, Kobayashi T, Shibayama J, Inaba S, Matsubara T, Yasuda T, Miwa K, Inoue M, Fujita T, Yakuta Y, Aburao T, Matsui T, Higashi K, Koga T, Hikishima K, Namura M, Horita Y, Ikeda M, Terai H, Gamou T, Tama N, Kimura R, Tsujimoto D, Nakahashi T, Ueda K, Ino H, Higashikata T, Kaneda T, Takata M, Yamamoto R, Yoshikawa T, Ohira M, Suematsu T, Tagawa S, Inoue T, Okada H, Kita Y, Fujita C, Ukawa N, Inoguchi Y, Ito Y, Araki T, Oe K, Minamoto M, Yokawa J, Tanaka Y, Mori K, Taguchi T, Kaku B, Katsuda S, Hirase H, Haraki T, Fujioka K, Terada K, Ichise T, Maekawa N, Higashi M, Okeie K, Kiyama M, Ota M, Todo Y, Aoyama T, Yamaguchi M, Noji Y, Mabuchi T, Yagi M, Niwa S, Takashima Y, Murai K, Nishikawa T, Mizuno S, Ohsato K, Misawa K, Kokado H, Michishita I, Iwaki T, Nozue T, Katoh H, Nakashima K, Ito S, Yamagishi M. Correction: Characterization of baseline clinical factors associated with incident worsening kidney function in patients with non-valvular atrial fibrillation: the Hokuriku-Plus AF Registry. Heart Vessels 2023; 38:412. [PMID: 36508013 DOI: 10.1007/s00380-022-02218-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Kenshi Hayashi
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.
| | - Yoshihiro Tanaka
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.,Center for Arrhythmia Research, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.,Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Toyonobu Tsuda
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Akihiro Nomura
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Noboru Fujino
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Hiroshi Furusho
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.,Department of Cardiology, Ishikawa Prefectural Central Hospital, 2-1, Kuratsuki-higashi, Kanazawa, Japan
| | - Norihiko Sakai
- Department of Nephrology and Laboratory Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa, Japan
| | - Yasunori Iwata
- Department of Nephrology and Laboratory Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa, Japan
| | - Soichiro Usui
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Kenji Sakata
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Takeshi Kato
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Hayato Tada
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Takashi Kusayama
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Keisuke Usuda
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Masa-Aki Kawashiri
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Rod S Passman
- Center for Arrhythmia Research, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.,Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Takashi Wada
- Department of Nephrology and Laboratory Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa, Japan
| | - Masakazu Yamagishi
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.,Osaka University of Human Sciences, Settsu, Osaka, Japan
| | - Masayuki Takamura
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Hagihara M, Hayashi H, Nakajima S, Imai Y, Nakano H, Uchida T, Inoue M, Miyawaki M, Ikeda N, Konuma R, Atsuta Y, Tanaka M, Imamura A. [Outcomes of COVID-19 due to omicron variant infection complicated with hematological disorders]. Rinsho Ketsueki 2023; 64:3-8. [PMID: 36775303 DOI: 10.11406/rinketsu.64.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
When the omicron variant became the most dominant severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) variant causing coronavirus disease 2019 (COVID-19) in Japan, 11 patients with hematological diseases infected with this new variant were treated at our institution. Among them, four of the five patients who had been treated with chemotherapy progressed to moderate-II COVID-19, and two of them died. In contrast, five of the six patients who did not receive the treatment remained at mild to moderate-I stage of COVID-19, except for a single case progressing to moderate-II COVID-19. While all four patients infused with anti-coronavirus monoclonal antibodies within 8 days after the onset survived, the other two patients, being withheld from treatment or treated later, died. In these two cases, anti-SARS-Cov-2 immunoglobulin G antibodies remained at low titers. Although the omicron variant is considered a less harmful SARS-Cov-2 variant, patients with hematological disorders, particularly those who are immunosuppressed caused by chemotherapy, should be continuously cared for as they remain at a higher risk of severe COVID-19 due to insufficient or delayed anti-viral humoral immunity development. Thus, the rapid introduction of antiviral monoclonal antibodies together with anti-viral reagents may rescue these patients.
Collapse
Affiliation(s)
| | | | | | - Yui Imai
- Department of Hematology, Eiju General Hospital
| | | | | | | | | | | | - Ryosuke Konuma
- Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
| | - Yuya Atsuta
- Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
| | - Masaru Tanaka
- Division of Infectious Disease, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
| | - Akifumi Imamura
- Division of Infectious Disease, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
| |
Collapse
|
10
|
Watanabe S, Inoue M, Miyata M, Boda H. The effect of Daikenchuto on blood flow of the superior mesenteric artery and portal vein in ELBW: A prospective study. J Neonatal Perinatal Med 2023; 16:423-428. [PMID: 37718870 DOI: 10.3233/npm-230132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/19/2023]
Abstract
BACKGROUND Focal intestinal perforation (FIP) is a devastating complication of premature birth, and extremely low birth weight (ELBW) infants are at highest risk. This study aimed to evaluate the relationship of the superior mesenteric artery (SMA) and portal vein (PV) blood flow velocities to investigate the association between intestinal blood flow and FIP. In addition, the herbal formula Daikenchuto (TJ-100) is expected to improve intestinal blood flow disorders; therefore, we evaluated its effect. METHODS We conducted a prospective cohort study of 15 ELBW infants from January 2020 to August 2021. Measured variables included birth weight, 5-minute Apgar score, time of oral feeding initiation, ductus arteriosus (PDA) closure (percent), diastolic and systolic blood pressure, SMA and PV blood flow velocity, and FIP onset data. Fifteen infants were divided into three groups: a non-surgery group (Group I; 6), a surgery group with FIP (Group II; 4), and a TJ-100 administration group (Group III; 5). The main outcome parameters included SMA and PV blood flow velocities with TJ-100. RESULTS SMA and PV blood flow differed significantly for the SMA of Group I and the SMA and PV of Group III (P < 0.01, P = 0.01, and P = 0.04, respectively). There was a correlation between SMA and PV in Group III (P = 0.03). CONCLUSION TJ-100 may increase SMA and PV blood flow and improve intestinal blood flow in ELBW infants at risk of FIP. Therefore, the effects of TJ-100 should undergo further study.
Collapse
Affiliation(s)
- S Watanabe
- Department of Pediatric Surgery, Fujita Health University Hospital, Aichi, Japan
| | - M Inoue
- Department of Pediatric Surgery, Fujita Health University Hospital, Aichi, Japan
| | - M Miyata
- Department of Pediatric, Fujita Health University Hospital, Aichi, Japan
| | - H Boda
- Department of Pediatric, Fujita Health University Hospital, Aichi, Japan
| |
Collapse
|
11
|
Hagihara M, Sugi T, Hayashi H, Nakashima S, Ohara S, Imai Y, Nakano H, Uchida T, Inoue M, Mitamura K. [Analysis of anti-SARS-CoV-2 IgG antibody titers after mRNA booster vaccination in patients with nonmalignant hematological disorders]. Rinsho Ketsueki 2023; 64:133-136. [PMID: 36990734 DOI: 10.11406/rinketsu.64.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 03/31/2023]
Abstract
In our facility, anti-SARS-CoV-2 mRNA vaccines were given to 21 patients, including 8 with aplastic anemia (AA), 3 with pure red cell aplasia (PRCA), and 10 with immune thrombocytopenic purpura (ITP), and IgG antibody titers were assessed one month after vaccinations. After receiving both a second vaccine and a booster shot, all patients with AA/PRCA treated with cyclosporine A aside from one, had IgG titers that were lower than the median levels of healthy controls. Even if prednisolone (PSL) doses did not go over 10 mg/day, ITP patients receiving PSL therapy were unable to achieve adequate levels of IgG after booster immunizations.
Collapse
Affiliation(s)
| | | | | | | | - Shin Ohara
- Department of Hematology, Eiju General Hospital
| | - Yui Imai
- Department of Hematology, Eiju General Hospital
| | | | | | | | - Keiko Mitamura
- Department of Preventive Medicine, Eiju General Hospital
| |
Collapse
|
12
|
Kizawa R, Kuno M, Washino S, Shirotake S, Izumi K, Inoue M, Kagawa M, Takeshita H, Hyodo Y, Kawakami S, Saito K, Kageyama Y, Oyama M, Miyagawa T, Miura Y. 142P The predictive biomarker for immune-related adverse events (irAEs) in patients with metastatic renal cell carcinoma treated with the combination therapy of nivolumab plus ipilimumab: Musashino study-irAE. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
13
|
Nakayama T, Takeshita H, Kagawa M, Washino S, Shirotake S, Miura Y, Hyodo Y, Izumi K, Inoue M, Miyagawa T, Oyama M, Saito K, Kageyama Y, Kawakami S. 139MO Prognostic significance of the mechanism of inflammatory markers in advanced renal cell carcinoma patients treated with nivolumab plus ipilimumab. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
14
|
Fujii T, Hagihara M, Mitamura K, Nakashima S, Ohara S, Uchida T, Inoue M, Okuda M, Yasuhara A, Murakami J, Duong C, Iwatsuki-Horimoto K, Yamayoshi S, Kawaoka Y. Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan. Intern Med 2022; 61:1681-1686. [PMID: 35342138 PMCID: PMC9259303 DOI: 10.2169/internalmedicine.9209-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Objective Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread globally. Although the relationship between anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies and COVID-19 severity has been reported, information is lacking regarding the seropositivity of patients with particular types of diseases, including hematological diseases. Methods In this single-center, retrospective study, we compared SARS-CoV-2 IgG positivity between patients with hematological diseases and those with non-hematological diseases. Results In total, 77 adult COVID-19 patients were enrolled. Of these, 30 had hematological disorders, and 47 had non-hematological disorders. The IgG antibody against the receptor-binding domain of the spike protein was detected less frequently in patients with hematological diseases (60.0%) than in those with non-hematological diseases (91.5%; p=0.029). Rituximab use was significantly associated with seronegativity (p=0.010). Conclusion Patients with hematological diseases are less likely to develop anti-SARS-CoV-2 antibodies than those with non-hematological diseases, which may explain the poor outcomes of COVID-19 patients in this high-risk group.
Collapse
Affiliation(s)
- Takayuki Fujii
- Department of Hematology, Eiju General Hospital, Japan
- Division of Hematology, Department of Medicine, Keio University School of Medicine, Japan
| | | | - Keiko Mitamura
- Division of Infection Control, Eiju General Hospital, Japan
| | | | - Shin Ohara
- Department of Hematology, Eiju General Hospital, Japan
| | | | | | - Moe Okuda
- Division of Virology, Institute of Medical Science, University of Tokyo, Japan
| | - Atsuhiro Yasuhara
- Division of Virology, Institute of Medical Science, University of Tokyo, Japan
| | - Jurika Murakami
- Division of Virology, Institute of Medical Science, University of Tokyo, Japan
| | - Calvin Duong
- Division of Virology, Institute of Medical Science, University of Tokyo, Japan
| | | | - Seiya Yamayoshi
- Division of Virology, Institute of Medical Science, University of Tokyo, Japan
- The Research Center for Global Viral Diseases, Research Institute, National Center for Global Health and Medicine, Japan
| | - Yoshihiro Kawaoka
- Division of Virology, Institute of Medical Science, University of Tokyo, Japan
- The Research Center for Global Viral Diseases, Research Institute, National Center for Global Health and Medicine, Japan
| |
Collapse
|
15
|
Uchida T, Fujii T, Ohara S, Imai Y, Inoue M, Harada Y, Harada H, Hagihara M. [Novel germline SAMD9 mutation in an elderly patient with myelodysplastic syndrome]. Rinsho Ketsueki 2022; 63:865-869. [PMID: 36058856 DOI: 10.11406/rinketsu.63.865] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
An 80-year-old Japanese male patient presented to our hospital with complaints of fatigue. His peripheral blood tests revealed pancytopenia with predominant lymphocytes and without blasts. The bone marrow (BM) aspiration was unsuccessful due to a dry tap, and the subsequent BM biopsy revealed hypocellular marrow with fibrosis. He was diagnosed with myelodysplastic syndrome (MDS) with excess blasts (EB)-2 based on CD34-positive cells. The chromosome analysis of the BM revealed monosomy 7, and the SAMD9 W22* mutation was detected (variant allele frequency [VAF] of 51.22%) using next-generation sequencing. An identical mutation was observed in the buccal mucosa (VAF of 50%), which was confirmed as a germline mutation. The SAMD9 gene mutation is reported as one of the causative genes for MIRAGE syndrome and child-onset MDS. The present case was considered a loss-of-function mutation due to the near full-length SAMD9 deletion. This is the first adult case of MDS with SAMD9 W22* as a germline mutation.
Collapse
Affiliation(s)
| | | | - Shin Ohara
- Department of Hematology, Eiju General Hospital
| | - Yui Imai
- Department of Hematology, Eiju General Hospital
| | | | - Yuka Harada
- Clinical Research Support Center, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
| | - Hironori Harada
- Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences
| | | |
Collapse
|
16
|
Fujii T, Ohara S, Uchida T, Inoue M, Hagihara M, Miyamoto K. [Rapid response of secondary plasma cell leukemia after carfilzomib and dexamethasone therapy]. Rinsho Ketsueki 2022; 63:111-113. [PMID: 35264500 DOI: 10.11406/rinketsu.63.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
An 83-year-old man was admitted to our hospital due to a recurrence of multiple myeloma, accompanied by the appearance of plasma cells in the peripheral blood (PB). Subsequently, he was diagnosed with secondary plasma cell leukemia (sPCL). A chemotherapy regimen of carfilzomib and dexamethasone (Cd) combination therapy was selected, and 15 days later, plasma cells completely disappeared from the PB. Cd therapy was continued, and the free kappa chain levels normalized. Three months later, M-protein could not be detected using serum electrophoresis. This is a valuable report wherein Cd combination therapy was successful in treating sPCL.
Collapse
Affiliation(s)
- Takayuki Fujii
- Department of Hematology, Eiju General Hospital
- Division of Hematology, Department of Medicine, Keio University School of Medicine
| | - Shin Ohara
- Department of Hematology, Eiju General Hospital
| | | | | | | | - Ko Miyamoto
- Department of Chemotherapy, Tokyo Metropolitan Geriatric Hospital
| |
Collapse
|
17
|
Hagihara M, Imai Y, Uchida T, Ohara S, Inoue M, Sugi T, Mitamura K. Successful Elimination of SARS-CoV-2 Following Vaccination with BNT162b2 after Prolonged Viral Infection in an Immunocompromised Lymphoma Patient. Intern Med 2022; 61:2215-2219. [PMID: 35850990 PMCID: PMC9381351 DOI: 10.2169/internalmedicine.9513-22] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
A 52-year-old man with mantle cell lymphoma treated with bendamustine and rituximab developed prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Despite elevated titers of anti-spike IgG antibody, protracted pancytopenia persisted for more than six months. Finally, the anti-SARS CoV-2 vaccine, BNT162b2, was administered, which improved his blood cell count and eliminated the virus. The increased anti-spike IgG titer and lymphocyte count after vaccination suggested that both humoral and cellular immunity acted in coordination to eliminate the virus.
Collapse
Affiliation(s)
| | - Yui Imai
- Department of Hematology, Eiju General Hospital, Japan
| | | | - Shin Ohara
- Department of Hematology, Eiju General Hospital, Japan
| | | | - Tomiyuki Sugi
- Department of Pharmacy, Eiju General Hospital, Japan
| | - Keiko Mitamura
- Department of Preventive Medicine, Eiju General Hospital, Japan
| |
Collapse
|
18
|
Hagihara M, Ide S, Ohara S, Imai Y, Uchida T, Inoue M. [Complete response with tirabrutinib for relapsed and refractory Bing-Neel syndrome]. Rinsho Ketsueki 2022; 63:770-775. [PMID: 35922946 DOI: 10.11406/rinketsu.63.770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
A 62-year-old female patient was diagnosed with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) 8 years ago, which was resolved with rituximab (R) monotherapy. Five years ago, she experienced numbness of the lower limbs, followed by diminished lower limb muscle strength and hearing disturbance. PET-CT scans showed accumulations along the peripheral nerves of the upper and lower limbs together with clonal B lymphocytes in the cerebrospinal fluid, thus a diagnosis of relapse with Bing-Neel syndrome (BNS). After a temporal remission by high-dose cytarabine or bendamustine plus R regimens as salvage treatments, WM/LPL recurred for the third time accompanied by gait disturbances due to muscle weakness and urinary retention. Thus, tirabrultinib was started as a subsequent therapy, which significantly improved the neurological condition together with abnormal findings of magnetic resonance imaging or cerebrospinal fluids. This case is valuable since few relapsed BNS was reported in the literature with successful tirabrutinib treatment.
Collapse
Affiliation(s)
| | - Shiro Ide
- Department of Hematology, Eiju General Hospital
| | - Shin Ohara
- Department of Hematology, Eiju General Hospital
| | - Yui Imai
- Department of Hematology, Eiju General Hospital
| | | | | |
Collapse
|
19
|
Hagihara M, Sugi T, Uchida T, Ohara S, Imai Y, Inoue M, Mitamura K. [SARS-CoV2 anti-spike IgG response following COVID-19 mRNA vaccination (BNT162b2) in patients with hematological disorders]. Rinsho Ketsueki 2022; 63:247-253. [PMID: 35491212 DOI: 10.11406/rinketsu.63.247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
This is a prospective study conducted to determine the level of anti-spike IgG to SARS-CoV-2 2-6 weeks following the BNT162b2 vaccination in 125 patients with hematological disorders. Compared with healthy controls, patients with malignant lymphoma had lower rates of seropositivity and lower levels of antibody titer. Furthermore, patients who received rituximab (R)-containing chemotherapy had lower antibody titers than those who were not treated with R or who had completed R-containing chemotherapy more than 9 months earlier. Despite having 71% IgG-seropositivity, patients with multiple myeloma had lower antibody titers than the control group. Furthermore, patients receiving daratumumab-containing chemotherapy had lower antibody titers than those not receiving treatment. Moreover, patients with acute myeloid leukemia or myelodysplastic syndrome had lower antibody titers than the control group. Overall, the number of peripheral blood lymphocytes was significantly correlated with IgG titers, with seropositive patients having more peripheral blood lymphocytes than seronegative patients. Patients with severe immunosuppression, such as those with hematological disorders, often have impaired seroconversion with COVID-19 vaccination that should be taken into consideration by clinicians.
Collapse
Affiliation(s)
| | | | | | - Shin Ohara
- Department of Hematology, Eiju General Hospital
| | - Yui Imai
- Department of Hematology, Eiju General Hospital
| | | | - Keiko Mitamura
- Department of Preventive Medicine, Eiju General Hospital
| |
Collapse
|
20
|
Sugi T, Mita M, Yasu T, Kubo K, Kushi R, Hanai H, Ohara S, Uchida T, Inoue M, Hagihara M. Preceding bortezomib administration for a certain period reduces the risk of lenalidomide-induced skin rash. J Clin Pharm Ther 2021; 47:477-482. [PMID: 34778985 DOI: 10.1111/jcpt.13568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 10/25/2021] [Accepted: 11/01/2021] [Indexed: 11/29/2022]
Abstract
WHAT IS KNOWN AND OBJECTIVE It was previously reported that the incidence of lenalidomide (LEN)-induced skin rash is reduced by administration of bortezomib (BOR) prior to LEN administration in patients with multiple myeloma (MM). Therefore, we investigated whether LEN-induced skin rash is affected by the duration of BOR administration and the dosing interval between BOR and LEN administration. METHOD A retrospective investigation was conducted among MM patients who received BOR treatment prior to LEN treatment in Eiju General Hospital from May 2010 to December 2020. We investigated whether the BOR administration duration and interval duration from the completion of BOR administration to the initial LEN administration affect the development of LEN-induced skin rash. RESULT AND DISCUSSION Twenty-eight of the 81 patients exhibited LEN-induced skin rash (34.6%). The administered duration, but not the interval, was significantly longer in the group without skin rash. Cut-off values were set for the duration of administration and interval, which were 35 days and 30 days, respectively. Multivariate analysis was performed on patients which are administered duration of more than 35 days and intervals of less than 30 days, and those who are not applicable. A significant difference was observed in the incidence of skin rash for each factor. WHAT IS NEW AND CONCLUSION The risk of reduced LEN-induced skin rash is affected not only by the presence of prior BOR administration, but also by the duration of BOR and the interval from the completion of BOR to the initial LEN administration.
Collapse
Affiliation(s)
- Tomiyuki Sugi
- Department of Pharmacy, Eiju General Hospital, Taito-ku, Japan.,Department of Cardiovascular Pharmacology, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Kiyose, Japan
| | - Mitsuo Mita
- Department of Cardiovascular Pharmacology, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Kiyose, Japan
| | - Takeo Yasu
- Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Kiyose, Japan
| | - Kana Kubo
- Department of Pharmacy, Eiju General Hospital, Taito-ku, Japan
| | - Ryota Kushi
- Department of Pharmacy, Eiju General Hospital, Taito-ku, Japan
| | - Homare Hanai
- Department of Pharmacy, Eiju General Hospital, Taito-ku, Japan
| | - Shin Ohara
- Department of Hematology, Eiju General Hospital, Taito-ku, Japan
| | - Tomoyuki Uchida
- Department of Hematology, Eiju General Hospital, Taito-ku, Japan
| | - Morihiro Inoue
- Department of Hematology, Eiju General Hospital, Taito-ku, Japan
| | - Masao Hagihara
- Department of Hematology, Eiju General Hospital, Taito-ku, Japan
| |
Collapse
|
21
|
Hagihara M, Ohara S, Uchida T, Inoue M. Practical management of patients with hematological diseases during the COVID-19 pandemic in Japan. Int J Hematol 2021; 114:709-718. [PMID: 34669154 PMCID: PMC8527309 DOI: 10.1007/s12185-021-03175-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2021] [Accepted: 06/09/2021] [Indexed: 12/15/2022]
Abstract
Polymerase chain reaction (PCR) tests cannot always detect the SARS-CoV-2 virus, possibly due to differences in sensitivity between sample types. Under these circumstances, immunochromatography may serve as an alternative method to detect anti-SARS-CoV-2 IgG antibodies that indicate a history of infection. In our analysis of patients with severe COVID-19 infection, we found that 14 of 19 serum samples were positive for IgG antibodies, whereas 6 of 10 samples from patients with asymptomatic or mild cases were negative. Two patients with immune thrombocytopenia who were treated with prednisolone experienced aggressive COVID-19-related respiratory failure and eventually died. Patients not in remission and those who received steroid-based chemotherapy had a higher risk of death, and patients with lymphoid malignancies including lymphoma and myeloma died in larger numbers than those with myeloid malignancies. A stricter cohorting strategy based on repeat PCR tests or isolation to a private room should be adopted in routine care in hematology departments to prevent viral spread to the environment.
Collapse
|
22
|
Unoki T, Kametani M, Matsuura J, Toyofuku T, Konami Y, Suzuyama H, Inoue M, Horio E, Yufu T, Kodama K, Yamamuro M, Taguchi E, Sawamura T, Nakao K, Sakamoto T. Percutaneous coronary intervention on combined VA-ECMO and IMPELLA (ECPELLA) support may reduce myocardial damage in cardiogenic shock patients with STEMI who required mechanical circulatory support. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is an effective therapeutic modality for patients with cardiogenic shock (CS) including STEMI. The VA-ECMO maintains end-organ perfusion, however, it significantly increases damaged left ventricular (LV) afterload. Combined treatment of VA-ECMO and a micro-axial Impella pump, ECPELLA, simultaneously provides systemic circulatory support and LV loading reduction (LV unloading). Studies in ischemic animal models displayed that LV unloading reduced myocardial size. However, it remains unknown whether LV unloading effect by ECPELLA during percutaneous coronary intervention (PCI) can reduce myocardial damage in human STEMI patients with severe cardiogenic shock.
Purpose
This study was to assess whether PCI on ECPELLA support can reduce myocardial damage in STEMI patients with severe cardiogenic shock.
Methods
Sixteen consecutive patients with STEMI and lethal CS (SCAI stage E) were enrolled. All patients suffered from cardiac arrest. Fifteen patients (94%) underwent extracorporeal cardiopulmonary resuscitation using VA-ECMO. From October 2018 to November 2019, PCI was carried out on VA-ECMO support and the mechanical circulatory support (MCS) modality during PCI was switched to ECPELLA since December 2019. There were 8 patients who underwent PCI on ECPELLA support (ECPELLA-PCI) and 8 patients who underwent PCI on single VA-ECMO support (ECMO-PCI). All patients in ECMO-PCI group were escalated to ECPELLA after PCI. Therefore, the difference between groups was timing of LV unloading, i.e., pre-PCI or post-PCI condition. We assessed total MCS flow during PCI, and peak and time course changes in CK-MB levels from days 0 to 3.
Results
There were no significant differences in age, rate of male sex, body surface area, shockable rhythm, serum lactate levels, and door to MCS time. Patients in ECPELLA-PCI had significantly longer door to recanalization time (73min in ECPELLA vs. 49min in VA-ECMO, p<0.05), and higher total MCS flow during PCI (3.1 L/min/sqM vs. 2.0 L/min/sqM, p<0.05). Peak and the area under the curves (AUC) from day 0 to day 3 of CK-MB in ECPELLA-PCI were significantly lower than ECMO-PCI group (peak CK-MB 120 vs. 524 IU/L and CK-MB AUC 143 vs. 464 IU/L*Day, respectively, p<0.05). While all patients received red blood cell (RBC) and plasma (PL) transfusions, ECPELLA-PCI required larger amount of RBC and PL transfusions (p<0.05).
Conclusion
The ECPELLA-PCI appeared to reduce myocardial damage shown by peak and AUC of CK-MB levels. Lager amount of blood transfusion is a major drawback of this treatment modality. Further studies are necessary whether ECPELLA-PCI is an effective revascularization approach for myocardial damage reduction with favorable mid- and long-term outcome in patients with STEMI with severe cardiogenic shock.
Funding Acknowledgement
Type of funding sources: None. Total MCS FLow and Ttoal MCS flow indexPeak CK-MB and CK-MB AUC
Collapse
Affiliation(s)
- T Unoki
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - M Kametani
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - J Matsuura
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - T Toyofuku
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - Y Konami
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - H Suzuyama
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - M Inoue
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - E Horio
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - T Yufu
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - K Kodama
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - M Yamamuro
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - E Taguchi
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - T Sawamura
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - K Nakao
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - T Sakamoto
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| |
Collapse
|
23
|
Abe M, Tsunawaki S, Dejonckheere M, Cigolle CT, Phillips K, Rubinstein EB, Matsuda M, Fetters MD, Inoue M. Practices and perspectives of primary care physicians in Japan and the United States about diagnosing dementia: a qualitative study. BMC Geriatr 2021; 21:540. [PMID: 34635089 PMCID: PMC8503990 DOI: 10.1186/s12877-021-02457-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Accepted: 08/30/2021] [Indexed: 11/29/2022] Open
Abstract
Background While dementia is a common problem in Japan and the US, primary care physicians' practices and perspectives about diagnosing dementia in these different healthcare systems are unknown. Methods Qualitative research was conducted in an ethnographic tradition using semi-structured interviews and thematic analysis in primary care settings across Japan and in the Midwest State of Michigan, US. Participants were a total of 48 primary care physicians, 24 each from Japan and the US participated. Both groups contained a mixture of geographic areas (rural/urban), gender, age, and years of experience as primary care physicians. Results Participants in Japan and the US voiced similar practices for making the diagnosis of dementia and held similar views about the desired benefits of diagnosing dementia. Differences were found in attitudes about the appropriate timing of formally diagnosing dementia. Japanese physicians tended to make a formal diagnosis when problems that would benefit from long-term care services emerged for family members. US physicians were more proactive in diagnosing dementia in the early stages by screening for dementia in health check-ups and promoting advance directives when the patients were still capable of decision-making. Views about appropriate timing of diagnostic testing for dementia in the two systems reflect what medical or nursing care services physicians can use to support dementia patients and caregivers. Conclusions Benefits of making the diagnosis included the need to activate the long-term care services in Japan and for early intervention and authoring advance directives in the US. Testing to establish an early diagnosis of dementia by primary care physicians only partly relates to testing and treatment options available. Benefits of making the diagnosis included the need to activate the long-term care services in Japan and for early intervention and authoring advance directives in the US. Supplementary Information The online version contains supplementary material available at 10.1186/s12877-021-02457-7.
Collapse
Affiliation(s)
- M Abe
- Department of Family and Community Medicine, Hamamatsu University School of Medicine, Shizuoka, Hamamatsu, Japan
| | - S Tsunawaki
- Omaezaki Family Medicine Center, Shizuoka, Omaezaki, Japan.,Shizuoka Family Medicine Program, Shizuoka, Hamamatsu, Japan
| | - M Dejonckheere
- Department of Family Medicine, University of Michigan, 1018 Fuller Street, Ann Arbor, MI, 48104, USA
| | - C T Cigolle
- Department of Family Medicine, University of Michigan, 1018 Fuller Street, Ann Arbor, MI, 48104, USA.,Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.,VA Ann Arbor Healthcare System (VAAHS) Geriatric Research Education and Clinical Center (GRECC), Ann Arbor, MI, USA
| | - K Phillips
- VA Ann Arbor Healthcare System (VAAHS) Geriatric Research Education and Clinical Center (GRECC), Ann Arbor, MI, USA
| | - E B Rubinstein
- Department of Sociology and Anthropology, North Dakota State University, Fargo, North Dakota, USA
| | - M Matsuda
- Shizuoka Family Medicine Program, Shizuoka, Hamamatsu, Japan.,Kikugawa Family Medicine Center, Shizuoka, Kikugawa, Japan
| | - M D Fetters
- Department of Family Medicine, University of Michigan, 1018 Fuller Street, Ann Arbor, MI, 48104, USA. .,The School of Health Humanities, Peking University Health Science Center, Beijing, China.
| | - M Inoue
- Department of Family and Community Medicine, Hamamatsu University School of Medicine, Shizuoka, Hamamatsu, Japan
| |
Collapse
|
24
|
Tanboon J, Inoue M, Saito Y, Hayashi S, Noguchi S, Okiyama N, Fujimoto M, Nishino I. AUTOIMMUNE & INFLAMMATORY NMD. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
25
|
Ohara S, Fujii T, Ide S, Uchida T, Inoue M, Hagaihara M. Clinical characteristics and risk factors associated with nosocomial COVID-19 infection in patients with hematological disorders in Japan. Int J Hematol 2021; 114:719-724. [PMID: 34152562 PMCID: PMC8215476 DOI: 10.1007/s12185-021-03172-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2020] [Revised: 06/06/2021] [Accepted: 06/09/2021] [Indexed: 11/08/2022]
Abstract
Patients with cancer are considered at high risk of acquiring coronavirus disease (COVID-19). To identify patients who are likely to be diagnosed with severe COVID-19, we analyzed the risk factors for mortality in patients admitted to the hematology department at our institute. The mortality rate of all patients was as high as 62% (21 of the 34 patients), and most of these patients had malignant malignancies. Patients before an achievement of remission had a 10.8-fold higher risk of death than those in remission. The group receiving chemotherapy with steroids had a shorter survival time and had an 8.3-fold higher risk of death than that receiving chemotherapy without steroids. During the COVID-19 pandemic, it is necessary to carefully monitor or follow-up patients with active diseases and patients receiving steroid-containing chemotherapy.
Collapse
Affiliation(s)
- Shin Ohara
- Eiju General Hospital, 2-23-16, Higashi-Ueno, Taito, Tokyo, Japan.
| | - Takayuki Fujii
- Eiju General Hospital, 2-23-16, Higashi-Ueno, Taito, Tokyo, Japan
| | - Shiro Ide
- Eiju General Hospital, 2-23-16, Higashi-Ueno, Taito, Tokyo, Japan
| | - Tomoyuki Uchida
- Eiju General Hospital, 2-23-16, Higashi-Ueno, Taito, Tokyo, Japan
| | - Morihiro Inoue
- Eiju General Hospital, 2-23-16, Higashi-Ueno, Taito, Tokyo, Japan
| | - Masao Hagaihara
- Eiju General Hospital, 2-23-16, Higashi-Ueno, Taito, Tokyo, Japan
| |
Collapse
|
26
|
Sugi T, Mita M, Yasu T, Ohara S, Uchida T, Inoue M, Hagihara M. Simple desensitization protocol for multiple myeloma patients with lenalidomide-induced skin rash: Case series. J Clin Pharm Ther 2021; 46:1792-1795. [PMID: 33960000 DOI: 10.1111/jcpt.13433] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Revised: 03/31/2021] [Accepted: 04/19/2021] [Indexed: 11/29/2022]
Abstract
WHAT IS KNOWN AND OBJECTIVE Skin rash is one of the typical side effects of lenalidomide (LEN) treatment. Desensitization therapies have been reported to be effective in patients with severe skin rash caused by LEN. However, they have proved impractical due to the complexity of the protocols. CASE SUMMARIES We present 5 patients who developed severe LEN-induced skin rash. The five patients received our simple, slow desensitization protocol, and all were re-administered LEN with no adverse reaction. WHAT IS NEW AND CONCLUSION Our simpler and slow desensitization protocol, which desensitizes the patients without reducing the effect of LEN, includes drug holidays, similar to the usual LEN dosing schedule, and moreover is recommended as a treatment option especially for elderly patients with no housemate to help with medical management.
Collapse
Affiliation(s)
- Tomiyuki Sugi
- Department of Pharmacy, Eiju General Hospital, Taito-ku, Japan.,Department of Cardiovascular Pharmacology, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Kiyose, Japan
| | - Mitsuo Mita
- Department of Cardiovascular Pharmacology, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Kiyose, Japan
| | - Takeo Yasu
- Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Kiyose, Japan
| | - Shin Ohara
- Department of Hematology, Eiju General Hospital, Taito-ku, Japan
| | - Tomoyuki Uchida
- Department of Hematology, Eiju General Hospital, Taito-ku, Japan
| | - Morihiro Inoue
- Department of Hematology, Eiju General Hospital, Taito-ku, Japan
| | - Masao Hagihara
- Department of Hematology, Eiju General Hospital, Taito-ku, Japan
| |
Collapse
|
27
|
Khot MI, Levenstein M, Coppo R, Kondo J, Inoue M, Kapur N, Jayne DG. O23: CHARACTERISING PATIENT-DERIVED COLORECTAL CANCER TISSUE-ORIGINATED ORGANOIDAL SPHEROIDS FOR HIGH-THROUGHPUT MICROFLUIDIC APPLICATIONS. Br J Surg 2021. [DOI: 10.1093/bjs/znab117.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Introduction
Three-dimensional (3D) cell models have gained reputation as better representations of in vivo cancers as compared to monolayered cultures. Recently, patient tumour tissue-derived organoids have advanced the scope of complex in vitro models, by allowing patient-specific tumour cultures to be generated for developing new medicines and patient-tailored treatments. Integrating 3D cell and organoid culturing into microfluidics, can streamline traditional protocols and allow complex and precise high-throughput experiments to be performed with ease.
Method
Patient-derived colorectal cancer tissue-originated organoidal spheroids (CTOS) cultures were acquired from Kyoto University, Japan. CTOS were cultured in Matrigel and stem-cell media. CTOS were treated with 5-fluorouracil and cytotoxicity evaluated via fluorescent imaging and ATP assay. CTOS were embedded, sectioned and subjected to H&E staining and immunofluorescence for ABCG2 and Ki67 proteins. HT29 colorectal cancer spheroids were produced on microfluidic devices using cell suspensions and subjected to 5-fluorouracil treatment via fluid flow. Cytotoxicity was evaluated through fluorescent imaging and LDH assay.
Result
5-fluorouracil dose-dependent reduction in cell viability was observed in CTOS cultures (p<0.01). Colorectal CTOS cultures retained the histology, tissue architecture and protein expression of the colonic epithelial structure. Uniform 3D HT29 spheroids were generated in the microfluidic devices. 5-fluorouracil treatment of spheroids and cytotoxic analysis was achieved conveniently through fluid flow.
Conclusion
Patient-derived CTOS are better complex models of in vivo cancers than 3D cell models and can improve the clinical translation of novel treatments. Microfluidics can streamline high-throughput screening and reduce the practical difficulties of conventional organoid and 3D cell culturing.
Take-home message
Organoids are the most advanced in vitro models of clinical cancers. Microfluidics can streamline and improve traditional laboratory experiments.
Collapse
Affiliation(s)
- MI Khot
- School of Medicine, University of Leeds, UK
- School of Mechanical Engineering, University of Leeds, UK
| | - M Levenstein
- School of Mechanical Engineering, University of Leeds, UK
| | - R Coppo
- Graduate School of Medicine, Kyoto University, Japan
| | - J Kondo
- Graduate School of Medicine, Kyoto University, Japan
| | - M Inoue
- Graduate School of Medicine, Kyoto University, Japan
| | - N Kapur
- School of Mechanical Engineering, University of Leeds, UK
| | - DG Jayne
- School of Medicine, University of Leeds, UK
| |
Collapse
|
28
|
Hagihara M, Ohara S, Uchida T, Inoue M. [Practical management of the patients with hematological diseases during the COVID-19 pandemic in Japan]. Rinsho Ketsueki 2021; 62:115-124. [PMID: 33678770 DOI: 10.11406/rinketsu.62.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
PCR assay cannot always detect the SARS-CoV2 virus, which might be due to differences in the sensitivities of each sampling site. Under these circumstances, immunochromatography may serve as an alternative method to detect anti-SARS-CoV-2 IgG antibodies that can demonstrate a history of infection. In patients with severe COVID-19 infection, 14 of 19 serum samples were shown to be positive, whereas 6 of 10 samples from patients with asymptomatic or mild cases were negative for IgG antibodies. Two patients with immune thrombocytopenia, who were treated with prednisolone, experienced aggressive behavior of COVID-19-related respiratory failure and eventually died. Patients who were before an achievement of remission and those who received steroid-based chemotherapy possessed a higher risk of death, and more deaths were observed in patients with lymphoid malignancies including lymphoma and myeloma compared with those with myeloid malignancies. As for daily medical care in hematological department, a stricter cohorting strategy using repeat PCR tests or isolation to a private room should be adopted in order to prevent viral spread to the environment.
Collapse
|
29
|
Sugi T, Nishigami Y, Saigo H, Hanai H, Takabatake K, Mita M, Ohara S, Ide S, Uchida T, Inoue M, Hagihara M. Analysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma. Leuk Lymphoma 2021; 62:1405-1410. [DOI: 10.1080/10428194.2021.1876867] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Tomiyuki Sugi
- Department of Pharmacy, Eiju General Hospital, Tokyo, Japan
- Department of Cardiovascular Pharmacology, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Kiyose, Japan
| | | | - Hirohisa Saigo
- Department of Pharmacy, Eiju General Hospital, Tokyo, Japan
| | - Homare Hanai
- Department of Pharmacy, Eiju General Hospital, Tokyo, Japan
| | | | - Mitsuo Mita
- Department of Cardiovascular Pharmacology, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Kiyose, Japan
| | - Shin Ohara
- Department of Hematology, Eiju General Hospital, Tokyo, Japan
| | - Shiro Ide
- Department of Hematology, Eiju General Hospital, Tokyo, Japan
| | - Tomoyuki Uchida
- Department of Hematology, Eiju General Hospital, Tokyo, Japan
| | - Morihiro Inoue
- Department of Hematology, Eiju General Hospital, Tokyo, Japan
| | - Masao Hagihara
- Department of Hematology, Eiju General Hospital, Tokyo, Japan
| |
Collapse
|
30
|
Fujii T, Saito H, Ide S, Ohara S, Uchida T, Inoue M, Hagihara M, Kushimoto K, Nishiura M, Oashi A, Ochi J. [Successful steroid pulse therapy for COVID-19 associated respiratory failure initially mimicking bortezomib-induced lung injury]. Rinsho Ketsueki 2021; 62:30-34. [PMID: 33551422 DOI: 10.11406/rinketsu.62.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
From December 2019, a 71-year-old male underwent three cycles of a combination therapy of pomalidomide, bortezomib, and dexamethasone for relapsed multiple myeloma and a very good partial response was achieved. In March 2020, he developed a fever of 38.9°C and computed tomography revealed bilateral ground-glass opacities. Antibiotic therapy was ineffective. Bronchoscopy was performed and bortezomib-induced lung injury was initially suspected. Due to respiratory exacerbation, high-dose steroid therapy was administered, which resulted in a dramatic improvement of the patient's respiratory failure. Thereafter, reverse transcription polymerase chain reaction performed on a preserved bronchial lavage sample tested positive, and thus his diagnosis was corrected to COVID-19 pneumonia. It is difficult to discriminate COVID-19 pneumonia from drug-induced lung disease, as both disorders can present similar ground-glass opacities on computed tomography. Therefore, with this presented case, we summarize our experience with steroid therapy for COVID-19 associated respiratory distress at our institution.
Collapse
Affiliation(s)
| | | | - Shiro Ide
- Department of Hematology, Eiju General Hospital
| | - Shin Ohara
- Department of Hematology, Eiju General Hospital
| | | | | | | | | | - Miho Nishiura
- Department of Respiratory Medicine, Eiju General Hospital
| | - Ayano Oashi
- Department of Respiratory Medicine, Eiju General Hospital
| | - Junichi Ochi
- Department of Respiratory Medicine, Eiju General Hospital
| |
Collapse
|
31
|
Hagihara M, Uchida T, Inoue M, Ohara S, Imai Y. [Severe thrombocytopenia after COVID-19 mRNA vaccination]. Rinsho Ketsueki 2021; 62:1684-1687. [PMID: 35022337 DOI: 10.11406/rinketsu.62.1684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
The Japanese Society of Hematology recently published on acute exacerbation of immune-mediated thrombocytopenia (ITP) after mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. In addition, there is a growing concern for the development of the newly diagnosed ITP after SARS-CoV-2 vaccination. Herein, we report two cases of severe thrombocytopenia associated with bleeding tendencies at 4 and 14 days after BNT162b2 mRNA vaccination. Platelet counts returned to normal following platelet transfusion or treatment with intravenous immunoglobulin and dexamethasone. To our knowledge at the time of the draft of this manuscript, nine cases of SARS-CoV-2 vaccine-induced ITP have been reported. Although most patients showed favorable clinical courses similar to that of our cases, critical thrombocytopenia can lead to unfavorable outcomes. A national survey may be required to examine the causal relationship between SARS-CoV-2 vaccination and the emergence of the newly diagnosed ITP and clinical outcomes of vaccine-induced thrombocytopenia.
Collapse
Affiliation(s)
| | | | | | - Shin Ohara
- Department of Hematology, Eiju General Hospital
| | - Yui Imai
- Department of Hematology, Eiju General Hospital
| |
Collapse
|
32
|
Ohara S, Ide S, Uchida T, Inoue M, Hua J, Hagihara M. [Multiple myeloma with light chain deposition disease showing needle-like crystal inclusions in plasma cells and macrophages in multiple organs]. Rinsho Ketsueki 2020; 61:1620-1624. [PMID: 33298657 DOI: 10.11406/rinketsu.61.1620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
A 57-year-old Japanese man was referred to our hospital with the chief complaint of dizziness. Our investigations showed pancytopenia that necessitated bone marrow evaluation; this evaluation revealed plasma cell proliferation that was accompanied by numerous needle-shaped crystal inclusions. Clinical and laboratory examinations were used to establish a diagnosis of multiple myeloma (MM) accompanied by Fanconi syndrome. He was administered treatment with bortezomib, lenalidomide, or thalidomide; however, he died after experiencing upper abdominal pain of unknown etiology. Histopathological examination showed needle-like inclusions in the liver and kidney and macrophages in the bone marrow, suggesting light chain deposition disease (LCDD) that could contribute to multi-organ injury. We report the rare case of a patient with needle-shaped inclusions in MM that caused LCDD.
Collapse
Affiliation(s)
- Shin Ohara
- Internal Medicine, Eiju General Hospital
| | - Shiro Ide
- Internal Medicine, Eiju General Hospital
| | | | | | - Jian Hua
- Internal Medicine, Eiju General Hospital
| | | |
Collapse
|
33
|
Ide S, Ohara S, Uchida T, Inoue M, Hagihara M. [HHV-8-positive Castleman's disease with rapidly progressing multiorgan failure mimicking TAFRO syndrome]. Rinsho Ketsueki 2020; 61:1497-1501. [PMID: 33162447 DOI: 10.11406/rinketsu.61.1497] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
A 60-year-old man was admitted to our hospital with multiple organ failure complicated by disseminated intravascular coagulation. He presented with thrombocytopenia, pleural effusion, ascites, high fever, and renal impairment, suggesting TAFRO syndrome. In addition to administering prednisolone, dialysis and mechanical ventilation were initiated for severe renal and respiratory insufficiencies, respectively. However, he died 5 days after admission. An autopsy was performed, resulting in the diagnosis of human herpesvirus (HHV)-8-positive plasma cell-type Castleman's disease. Furthermore, HHV-8 was detected in the vascular endothelium and lymph nodes on immunohistochemical study. His rapidly deteriorating clinical course with the lack of serum hypergammaglobulinemia is atypical for Castleman's disease. Therefore, HHV-8 may have incited the disorder's aggressive behavior, causing TAFRO syndrome.
Collapse
Affiliation(s)
- Shiro Ide
- Department of Hematology, Eiju General Hospital
| | - Shin Ohara
- Department of Hematology, Eiju General Hospital
| | | | | | | |
Collapse
|
34
|
Unoki T, Tamura Y, Nakayama T, Kametani M, Minami Y, Konami Y, Suzuyama H, Inoue M, Yuhu T, Kodama K, Yamamuro M, Taguchi E, Sawamura T, Nakao K, Sakamoto T. Combined use of VA-ECMO and IMPELLA (ECPELLA) as a possible strategy to improve outcomes in patients who underwent E-CPR. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Extracorporeal Cardio-Pulmonary Resuscitation (E-CPR) is an effective tool for patients with refractory cardiac arrest (CA). Since VA-ECMO provides strong afterload, IABP is often used to increase left ventricular load. Recently, in Japan, the effectiveness of VA-ECMO in combination with IMPELLA, a forward flow mechanical circulatory support device (ECPELLA) is gaining attention.
Purpose
We investigated usefulness of ECPELLA in patients with refractory CA.
Method
We reviewed 133 patients that had E-CPR from January 2012 through January 2020 {mean age: 67±15 years, male 65%, Out of hospital Cardiac Arrest (OHCA) 35%, Acute coronary Syndrome (ACS) 54%}. We divided these patients into ECMO with IMPELLA (ECPELLA group), ECMO with IABP (IABP group) and ECMO alone (ECMO alone group). The primary endpoint is 30-day survival and good neurological prognosis defined as CPC (cerebral performance categories) 1 or 2.
Result
During the study period, of the 133 patients, there were 20 in the ECPELLA group, 78 in the IABP group, 35 in the ECMO alone group. There were no significant differences in age in all three groups. There were more males, shockable rhythm, OHCA and ACS in the ECPELLA and IABP groups compared to the ECMO alone group. But there was no significant difference between the ECPELLA and IABP groups. Compared with other groups, ECPELLA had the shortest time from cardiac arrest to ECMO placement. Regarding endpoints, the rate of 30-day survival and favorable neurological prognosis were higher in the ECPELLA group, followed by the IABP group and then the ECMO alone group. (ECPELLA: 55% vs. IABP: 23% vs. ECMO alone: 9%; P=0.0009, ECPELLA: 35% vs. IABP: 13% vs. ECMO alone: 9%; P=0.04) Next, Kaplan Meier analysis was performed to analyze 30-day all-cause mortality. The ECPELLA group had a significantly higher survival rate (P=0.01 by log-rank test). Multivariate cox proportional hazard analysis including the age, OHCA, shockable rhythm, ACS, Collapse-to-ECMO under 60 min revealed that the age (hazard ratio [HR], 1.28 (10 years increase), 95% confidence interval [CI], 1.08–1.53, P=0.004) and Collapse-to-ECMO under 60 min (HR, 0.37, 95% CI, 0.21–0.68, P=0.001) or ECPELLA (HR, 0.46, 95% CI, 0.20–0.694, P=0.03) were significantly associated with mortality.
Conclusion
ECPELLA used with E-CPR is an effective tool to improve mortality and neurologic status.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- T Unoki
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - Y Tamura
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - T Nakayama
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - M Kametani
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - Y Minami
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - Y Konami
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - H Suzuyama
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - M Inoue
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - T Yuhu
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - K Kodama
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - M Yamamuro
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - E Taguchi
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - T Sawamura
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - K Nakao
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - T Sakamoto
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| |
Collapse
|
35
|
Diermayr V, Sarma S, Lee K, Ng P, Tong C, Soon V, Gan B, Qu Z, Tan Z, Han X, Phua L, Poh H, Gan A, Camat D, Weng R, Cheong E, Inoue M, Lezhava A, Tan I, Lim T. 99P Development of a qRT-PCR-based diagnostic test to identify colorectal cancer patients with recurrent R-Spondin gene fusions. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
36
|
Kabeya Y, Okubo M, Yonezawa S, Nakano H, Inoue M, Ogasawara M, Saito Y, Tanboon J, Indrawati L, Kumutpongpanich T, Chen Y, Tokumasu R, Iwamori T, Takano A, Nishino I. OMICs AND AI APPROACHES FOR MUSCLE DISEASES. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
37
|
Uchida T, Takagi Y, Mizuno A, Okamura H, Saito H, Ide S, Ohara S, Inoue M, Hagihara M. [Retrospective analysis of nosocomial COVID-19: a comparison between patients with hematological disorders and other diseases]. Rinsho Ketsueki 2020; 61:857-864. [PMID: 32908046 DOI: 10.11406/rinketsu.61.857] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Nosocomial coronavirus disease 2019 (COVID-19) had occurred at our hospital. We retrospectively analyzed the differences between patients with nosocomial COVID-19 and either hematological disease (n=40) or other diseases (n=57). The analysis was completed within 60 days for surviving patients. Among the patients with hematological disease and those with other diseases, there were 21 (52.5%) and 20 (35.1%) deaths, respectively. Although the patients with hematological disease received favipiravir more frequently than patients with other diseases (21 [52.5%] vs. 15 [35.3%], respectively; P<0.05), their median overall survival was poor (29 days; P=0.078). Furthermore, the median duration from oxygen therapy initiation to death or intubation was significantly shorter in the patients with hematological disease (5 days [range, 1-17 days] vs. 10 days [1-24 days], respectively; P<0.05). Furthermore, the patients with hematological disease and nosocomial COVID-19 exhibited more marked respiratory failure and poorer outcomes leading to death in a shorter time period than the patients with other diseases and nosocomial COVID-19.
Collapse
Affiliation(s)
| | - Yuki Takagi
- Department of Hematology, Eiju General Hospital
| | | | | | | | - Shiro Ide
- Department of Hematology, Eiju General Hospital
| | - Shin Ohara
- Department of Hematology, Eiju General Hospital
| | | | | |
Collapse
|
38
|
Uchida T, Ide S, Ohara S, Inoue M, Jian H, Yokoyama Y, Sakata-Yanagimoto M, Hagihara M. [Relapsed acute myeloid leukemia concomitant with TET2-mutated peripheral T-cell lymphoma, not otherwise specified]. Rinsho Ketsueki 2020; 60:1652-1656. [PMID: 31902816 DOI: 10.11406/rinketsu.60.1652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
A 70-year-old female was initially diagnosed with acute myeloid leukemia (AML) and achieved complete remission by conventional chemotherapy. She presented with leukocytosis and pleural effusion six years later, and was diagnosed with myelodysplastic/myeloproliferative neoplasms (MDS/MPN) by bone marrow (BM) analysis. Pyrexia and lymphadenopathy developed one year later, and lymph node biopsy confirmed peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). Chemotherapy achieved a partial remission. Fifty-two days after her last chemotherapy treatment, increased blasts in the peripheral blood along with marked lymphadenopathy were observed, which were considered to be indicative of the simultaneous development of AML and lymphoma. TET2 mutations were confirmed in BM and lymph node samples. Development of AML and PTCL-NOS might be due to clonal hematopoiesis associated with aging and chemotherapy.
Collapse
Affiliation(s)
| | - Shiro Ide
- Department of Hematology, Eiju General Hospital
| | - Shin Ohara
- Department of Hematology, Eiju General Hospital
| | | | - Hua Jian
- Department of Hematology, Eiju General Hospital
| | - Yasuhisa Yokoyama
- Department of Hematology, Faculty of Medicine, University of Tsukuba
| | | | | |
Collapse
|
39
|
Hagihara M, Ide S, Ohara S, Uchida T, Inoue M, Hua J. [Pomalidomide/cyclophosphamide/dexamethasone combination therapy for relapsed/refractory multiple myeloma accompanied by extramedullary lesions]. Rinsho Ketsueki 2020; 61:20-26. [PMID: 32023597 DOI: 10.11406/rinketsu.61.20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
We retrospectively evaluated the efficacy of pomalidomide/cyclophosphamide/dexamethasone (PCd) treatment in seven patients with extramedullary disease (EMD). Three of the seven patients achieved VGPR (very good partial response) with PCd therapy. We handled a patient complicated with secondary plasma cell leukemia, which was completely cured with PCd regimen and succeeded to autologous stem cell transplantation. In addition, there were no severe infections during the treatment period. This is the first report demonstrating the efficiency and tolerability of PCd treatment for EMD.
Collapse
Affiliation(s)
| | - Shiro Ide
- Department of Hematology, Eiju General Hospital
| | - Shin Ohara
- Department of Hematology, Eiju General Hospital
| | | | | | - Jian Hua
- Department of Hematology, Eiju General Hospital
| |
Collapse
|
40
|
Hagihara M, Ohara S, Ide S, Uchida T, Inoue M, Mitamura K. [Analysis of anti-SARS-CoV-2 IgG antibodies in hematologic patients with asymptomatic or mildly symptomatic COVID-19 infections]. Rinsho Ketsueki 2020; 61:1459-1463. [PMID: 33162440 DOI: 10.11406/rinketsu.61.1459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
At our institution, an outbreak of hospital-acquired coronavirus infection (COVID-19) occurred in the hematology department. We used immunochromatography to examine the anti-COVID-19 IgG antibody level in 10 COVID-19 positive patients who exhibited little or no symptoms. Six patients were negative for IgG antibody at an average of 26 days (range: 11-39 days) after the COVID-19 diagnosis. Among them, two had been negative on PCR twice and were discharged but subsequently became positive on PCR 2-4 weeks later and developed pneumonia. These patients were also positive for IgG antibody after the confirmed diagnosis based on PCR accompanied with the development of pneumonia. Our findings suggest an immune response delay to COVID-19 in immunocompromised patients, such as those with hematologic disorders. Thus, follow-up examinations with antibody testing are important in these patients.
Collapse
Affiliation(s)
| | - Shin Ohara
- Department of Hematology, Eiju General Hospital
| | - Shiro Ide
- Department of Hematology, Eiju General Hospital
| | | | | | | |
Collapse
|
41
|
Kunimasa K, Nakamura H, Sakai K, Kimura M, Inoue T, Tamiya M, Nishino K, Kumagai T, Nakatsuka S, Endo H, Inoue M, Nishio K, Imamura F. Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor. Ann Oncol 2019; 29:2145-2147. [PMID: 30099497 DOI: 10.1093/annonc/mdy312] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- K Kunimasa
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka City, Japan.
| | - H Nakamura
- Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka City, Japan
| | - K Sakai
- Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan
| | - M Kimura
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka City, Japan
| | - T Inoue
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka City, Japan
| | - M Tamiya
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka City, Japan
| | - K Nishino
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka City, Japan
| | - T Kumagai
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka City, Japan
| | - S Nakatsuka
- Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka City, Japan
| | - H Endo
- Department of Biochemistry, Osaka International Cancer Institute, Osaka City, Japan
| | - M Inoue
- Department of Biochemistry, Osaka International Cancer Institute, Osaka City, Japan; Department of Clinical Bio-resource Research and Development, Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - K Nishio
- Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan
| | - F Imamura
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka City, Japan
| |
Collapse
|
42
|
Okada S, Hattori A, Matsunaga T, Takamochi K, Oh S, Inoue M, Suzuki K. P1.17-10 Prediction of Visceral Pleural Invasion in c-N0 Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
43
|
Shimomura M, Tsunezuka H, Okada S, Ishihara S, Ishikawa N, Ikebe S, Furuya T, Kameyama K, Kitaoka S, Shimada J, Inoue M. P1.18-07 Postoperative Complications and Long-Term Survival Among Octogenarians Treated Surgically for Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
44
|
Okada S, Miyagawa-Hayashino A, Fujinami J, Kameyama K, Kitaoka S, Ishikawa N, Furuya T, Ikebe S, Ishihara S, Tsunezuka H, Shimomura M, Shimada J, Inoue M. EP1.01-73 Trousseau’s Syndrome Associated with Pulmonary Pleomorphic Carcinoma Showing Aggressive Features: A Case Report. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
45
|
Inoue M, Yoshida J, Oka S, Honda Y, Chikaishi Y, Yasuda D. P1.04-53 A High PD-L1 Expression in Non-Small Cell Lung Cancer Correlates with Expression of SPOP and CD8 Tumor-Infiltrating Lymphocytes. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.956] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
46
|
Shimada J, Okada S, Tsunezuka H, Shimomura M, Ishihara S, Inoue M, Naito Y. EP1.16-36 A Good Intestinal Bacterial Environment Can Reduce the Side Effects of Tyrosine Kinase Inhibitors and Enhance Their Anti-Cancer Effects. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2401] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
47
|
Okubo M, Iida A, Inoue M, Saito Y, Ogasawara M, Hayashi S, Noguchi S, Nishino I. EP.102Genetic diagnosis in large Japanese cohort using targeted re-sequencing system. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
48
|
Indrawati L, Noguchi S, Tanboon J, Ogasawara M, Saito Y, Kumutpongpanich T, Inoue M, Okubo M, Fukuda T, Sugie H, Goto Y, Iida A, Hayashi S, Nishino I. P.89Infantile-onset lipid storage myopathy. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
49
|
Yamashita T, Kamada H, Kanasaki S, Nagano K, Inoue M, Higashisaka K, Yoshioka Y, Tsutsumi Y, Tsunoda S. Ephrin type-A receptor 2 on tumor-derived exosomes enhances angiogenesis through the activation of MAPK signaling. Pharmazie 2019; 74:614-619. [PMID: 31685088 DOI: 10.1691/ph.2019.9474] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
Exosomes are potent players in the development of metastases and they play an important role in cancer angiogenesis and exacerbation. However, it is unclear how proteins on exosomes affect development of blood vessel networks. In this study, we focused on relationships between membrane proteins on exosomes and angiogenesis using human umbilical vein endothelial cells (HUVEC). Lung tumor cell-derived exosomes induced tube formation and growth of endothelial cells in vitro in a dose-dependent manner involving MAPK activation, but this was not seen in normal lung epithelial cells. Ephrin type-A receptor 2 (EphA2) was identified by proteomic analysis and an inhibition assays showed it is a major MAPK activator on exosomes. Thus EphA2 on exosomes participates in angiogenesis as a ligand of the ephrin signaling pathway. These results support the development of novel therapeutic strategies such as blockade of remote cancer communications through exosomes.
Collapse
|
50
|
Inoue M, Uchino S, Iida A, Noguchi S, Hayashi S, Takahashi T, Fujii K, Komaki H, Takeshita E, Nonaka I, Yoshizawa T, Van Lommel L, Schuit F, Goto Y, Mimaki M, Nishino I. METABOLIC DISTURBANCES IN NEUROMUSCULAR DISEASES. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|